Singapore: Isogenica has appointed CTC Laboratory Systems (CTCLS) of Tokyo, Japan, to represent its business in Japan. CTCLS is a leading force in the pharmaceutical research market in Japan. It is a leading solution provider, specialising in the integration of R&D support systems for life science companies.

The tie-up will help Isogenica find a new cutomer base in Japan for its innovative technology for antibody, protein and peptide design.

Dr Kevin Matthews, CEO, Isogenica, said, "The appointment of CTCLS is an important milestone for Isogenica and ensures that we can support our key customers in all the major world markets. We understand that direct personal contact, taking account of cultural and language differences, is fundamental to developing strong customer relationships. I am confident that CTCLS is the best organization to represent us and look forward to working with them to introduce Isogenica to the Japanese market as a whole as well as following-up on specific customer opportunities".

Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies. Founded in 2000 Isogenica has developed a unique capability in the field of protein engineering.